Literature DB >> 12208028

Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions.

Nele Samyn1, Gert De Boeck, Michelle Wood, Caroline T J Lamers, Dick De Waard, Karel A Brookhuis, Alain G Verstraete, Wim J Riedel.   

Abstract

In a double-blind placebo controlled study on psychomotor skills important for car driving (Study 1), a 75 mg dose of +/- 3,4-methylenedioxymethamphetamine (MDMA) was administered orally to 12 healthy volunteers who were known to be recreational MDMA-users. Toxicokinetic data were gathered by analysis of blood, urine, oral fluid and sweat wipes collected during the first 5h after administration. Resultant plasma concentrations varied from 21 to 295 ng/ml, with an average peak concentration of 178 ng/ml observed between 2 and 4h after administration. MDA concentrations never exceeded 20 ng/ml. Corresponding MDMA concentrations in oral fluid, as measured with a specific LC-MS/MS method (which required only 50 microl of oral fluid), generally exceeded those in plasma and peaked at an average concentration of 1215 ng/ml. A substantial intra- and inter-subject variability was observed with this matrix, and values ranged from 50 to 6982 ng/ml MDMA. Somewhat surprisingly, even 4-5h after ingestion, the MDMA levels in sweat only averaged 25 ng/wipe. In addition to this controlled study, data were collected from 19 MDMA-users who participated in a driving simulator study (Study 2), comparing sober non-drug conditions with MDMA-only and multiple drug use conditions. In this particular study, urine samples were used for general drug screening and oral fluid was collected as an alternative to blood sampling. Analysis of oral fluid samples by LC-MS/MS revealed an average MDMA/MDEA concentration of 1121 ng/ml in the MDMA-only condition, with large inter-subject variability. This was also the case in the multiple drug condition, where generally, significantly higher concentrations of MDMA, MDEA and/or amphetamine were detected in the oral fluid samples. Urine screening revealed the presence of combinations such as MDMA, MDEA, amph, cannabis, cocaine, LSD and psilocine in the multiple-drug condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208028     DOI: 10.1016/s0379-0738(02)00157-3

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  13 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

2.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

3.  MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.

Authors:  Allan J Barnes; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

4.  An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine.

Authors:  Beata Y Silber; Katherine Papafotiou; Rodney J Croft; Con K K Stough
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

5.  Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration.

Authors:  Nathalie A Desrosiers; Allan J Barnes; Rebecca L Hartman; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-08       Impact factor: 4.142

6.  Excretion of Delta9-tetrahydrocannabinol in sweat.

Authors:  Marilyn A Huestis; Karl B Scheidweiler; Takeshi Saito; Neil Fortner; Tsadik Abraham; Richard A Gustafson; Michael L Smith
Journal:  Forensic Sci Int       Date:  2007-05-03       Impact factor: 2.395

7.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

Review 8.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety.

Authors:  Karel A Brookhuis; Dick de Waard; Nele Samyn
Journal:  Psychopharmacology (Berl)       Date:  2004-01-09       Impact factor: 4.530

10.  Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat.

Authors:  Bruno S De Martinis; Allan J Barnes; Karl B Scheidweiler; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.